| Literature DB >> 30758472 |
Uirá Fernandes Teixeira1, Marcos Bertozzi Goldoni1, Fábio Luiz Waechter1, José Artur Sampaio1, Florentino Fernandes Mendes2, Paulo Roberto Ott Fontes1.
Abstract
BACKGROUND: After the publication of the first recommendations of ERAS Society regarding colonic surgery, the proposal of surgical stress reduction, maintenance of physiological functions and optimized recovery was expanded to other surgical specialties, with minimal variations. AIM: To analyze the implementation of ERAS protocols for liver surgery in a tertiary center.Entities:
Mesh:
Year: 2019 PMID: 30758472 PMCID: PMC6368150 DOI: 10.1590/0102-672020180001e1424
Source DB: PubMed Journal: Arq Bras Cir Dig ISSN: 0102-6720
Guidelines for enhanced recovery after liver surgery
| 1.Preadmission counseling |
| 2. Perioperative nutrition |
| 3.Perioperative oral immunonutrition |
| 4.Preoperative fasting and preoperative carbohydrate loading |
| 5.Oral bowel preparation |
| 6.Pre-anesthetic medication |
| 7.Prophylaxis against thromboembolism |
| 8.Perioperative steroids administration |
| 9.Antimicrobial prophylaxis and skin preparation |
| 10. Incision |
| 11. Minimally invasive approach |
| 12. Nasogastric intubation |
| 13. Drainage of the peritoneal cavity |
| 14. Preventing intraoperative hypothermia |
| 15. Postoperative nutrition and early oral intake |
| 16. Postoperative glycemic control |
| 17. Prevention of delayed gastric emptying |
| 18. Stimulation of bowel movement |
| 19. Early mobilization |
| 20. Analgesia |
| 21. Postoperative nausea and vomiting prophylaxis |
| 22. Fluid management |
| 23. Audit |
Characteristics of the groups.
| ERAS GROUP (35) | CONTROL GROUP (50) | p | |
| Age (years/max-min) | 58 (24-78) | 60 (22-82) | 0.280 |
| Gender (male/female) | 16/19 | 22/28 | 0.350 |
| Cirrhosis | 5 (14.3) | 9 (18) | 0.080 |
| Major hepatectomy | 9 (25.7) | 14 (28) | 0.430 |
| Hepatectomy technique | |||
| Right Hepatectomy | 3 (8.6) | 6 (12) | 0.093 |
| Left Hepatectomy | 5 (14.3) | 7 (14) | 0.530 |
| Trisectorectomy | 1 (2.9) | 1 (2) | 0.560 |
| Bisegmentectomy | 15 (42.9) | 21 (42) | 0.570 |
| Trisegmentectomy | 2 (5.7) | 0 | 0.130 |
| Atipical Resections | 9 (25.7) | 15 (30) | 0.059 |
| Liver pathology | |||
| Colorectal Liver Metastases | 13 (37.1) | 18 (36) | 0.610 |
| Liver Adenoma | 5 (14.3) | 7 (14) | 0.540 |
| Hepatocellular Carcinoma | 8 (22.9) | 12 (24) | 0.645 |
| Gallbladder Neoplasm | 1 (2.9) | 3 (6) | 0.124 |
| Intrahepatic Cholangiocarcinoma | 2 (5.7) | 2 (4) | 0.510 |
| Other | 6 (17.1) | 8 (16) | 0.420 |
Main outcomes after ERAS implementation.
| VARIABLES | ERAS (n=35) | CONTROL (n=50) | p |
| Length of hospital stay, median (min-max) | 5 (2-15) | 7 (3-22) | <0,001 |
| Immunonutrition | 0 (0,0) | 1 (2,0) | 0,928 |
| Carbohydrate loading | 28 (80) | 0 (0,0) | <0,001 |
| Oral bowel preparation | 0 (0,0) | 12 (24,0) | 0,001 |
| Pre-anesthetic medication | 0 (0,0) | 12 (24,0) | 0,001 |
| Anti-thrombotic prophylaxis | 34 (97,1) | 48 (96,0) | >0,999 |
| Perioperative steroid administration | 19 (54,3) | 8 (40,0) | 0,460 |
| Antimicrobial prophylaxis | 35 (100,0) | 48 (96,0) | 0,510 |
| Incision | 0,001 | ||
| J-shaped | 10 (29,4) | 3 (6,1) | |
| Bilateral subcostal | 10 (29,4) | 34 (69,4) | |
| Laparoscopy | 14 (40,0) | 12 (24,0) | 0,181 |
| Nasogastric intubation | 4 (11,4) | 31 (62,0) | <0,001 |
| Prophylactic abdominal drainage | 24 (68,6) | 46 (92,0) | 0,012 |
| Preventing intraoperative hypothermia | 33 (94,3) | 36 (94,7) | >0,999 |
| Postoperative nutrition POD1 | 32 (91,4) | 25 (50,0) | <0,001 |
| Postoperative glycemic control | 24 (68,6) | 29 (58,0) | 0,446 |
| Omental flap | 2 (5,7) | 0 (0,0) | 0,167 |
| Stimulation of bowel movement | 6 (17,1) | 6 (12,0) | 0,540 |
| Early mobilization | 29 (82,9) | 19 (38,0) | <0,001 |
| Analgesia | |||
| Intravenous | 17 (48,6) | 19 (38,0) | 0,455 |
| Epidural | 18 (51,4) | 31 (62,0) | 0,455 |
| Local | 14 (40,0) | 11 (22,0) | 0,121 |
| Postoperative nausea and vomiting prophylaxis | 31 (88,6) | 27 (54,0) | 0,001 |
| Fluid management | 27 (77,1) | 17 (81,0) | >0,999 |
| Audit | 35 (100,0) | - | - |
| Overall Complications | 8 (22.9) | 12 (24) | 0.878 |
| Dindo-Clavien ≥ 3 | 4 (11.4) | 7 (14) | 0.230 |
| Mortality | 0 | 1 (2) | 0.720 |